UK finds Roche bladder cancer drug too costly for routine use
LONDON (Reuters) - Britain's healthcare cost-effectiveness agency NICE has decided Roche's new immunotherapy drug Tecentriq is too expensive to justify its routine use to treat bladder cancer, but still hopes it can be used in certain circumstances.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Health | Immunotherapy | National Institute for Health and Clinical Excelle | UK Health